The Series A round was led by Syncona and included a £1m investment from the UCL Technology Fund.
"It’s really exciting to be in at the start of something that could potentially change the way things are done. By bringing together academia and commerce, Quell Therapeutics will be at the cutting edge of the research and development of this important field."
The funding round was co-led by Impulse VC and VentureSouq to support product development and international expansion.
"Tech-enabled services for the property industry are a super-hot trend right now. GuestReady is poised to disrupt this market as one of the fastest growing companies in the segment of short-term rental management."
The funding round was led by S2G Ventures with participation from AgFunder and the Scottish Investment Bank to support global expansion and product development.
"Indoor agriculture production is at a tipping point. Grocery and food service firms have never been more interested in adopting this in their future supply chain. Cost and quality of product will be critical to scale this adoption. IGS’s revolutionary technology has proven itself to reduce power consumption, improve ventilation and hence reduce the capital and human costs to deliver fresh and differentiated products to consumers,"
Silversmith Capital Partners and Farview Equity Partners led a £53.7m investment to fund global expansion and AI innovation.
"This investment will provide Unily with the potential to disrupt the global digital experiences marketplace at greater pace and with broader reach than ever before."
HPE Growth led the Series A round to support the telemedicine provider's entry into statutory healthcare systems in Europe.
"Zava offers a unique and highly scalable model to deliver a more convenient healthcare experience to patients while radically improving the efficiency of healthcare professionals, enabling healthcare systems to reduce the overall costs associated with primary care. We are excited to be working with David and his team to expand Zava into statutory healthcare systems and bring Zava in a first step to the rest of Europe."